Protara Therapeutics (TARA) Other Accumulated Expenses (2013 - 2026)

Protara Therapeutics' Other Accumulated Expenses history runs 12 years deep, the most recent figure standing at $176000.0 for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 22.12% year-over-year to $176000.0; the TTM figure through Mar 2026 stood at $176000.0 (down 22.12% YoY), while the FY2025 annual figure was $279000.0, up 106.67% from the prior year.
• Other Accumulated Expenses was $176000.0 for Q1 2026 at Protara Therapeutics, down from $279000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $368000.0 in Q3 2024 to a low of $79000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $192235.3 across 5 years, with a median of $178000.0 in 2022.
• The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses plunged 71.99% in 2022, then surged 354.32% in 2024.
• A 5-year view of Other Accumulated Expenses shows it stood at $182000.0 in 2022, then retreated by 1.1% to $180000.0 in 2023, then decreased by 25.0% to $135000.0 in 2024, then surged by 106.67% to $279000.0 in 2025, then plunged by 36.92% to $176000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $176000.0 (Q1 2026), $279000.0 (Q4 2025), and $329000.0 (Q3 2025), per Business Quant data.